Legend Biotech (LEGN) has released an update.
Legend Biotech has reported positive outcomes from the Phase 3 CARTITUDE-4 trial, showing that its cell therapy CARVYKTI® significantly improves overall survival in patients with relapsed and lenalidomide-refractory multiple myeloma. The results, which add to the evidence supporting CARVYKTI®’s benefits, will be used for global regulatory label updates following its recent FDA approval for multiple myeloma treatment after at least one prior therapy. Safety profiles remained consistent with no new concerns, reinforcing the therapy’s promise for patients with this incurable disease.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
